New insights into MS treatment
Posted: Mon May 18, 2015 3:06 am
Data from two Novartis phase III clinical trials show that adding brain shrinkage (brain volume loss) to an existing tool to assess multiple sclerosis activity (m-Rio) will give a more precise prediction of the likelihood of future disability progression.... Read More - http://www.ms-uk.org/gilenya